Robeco Institutional Asset Management B.V. Sells 5,594 Shares of Edwards Lifesciences Corporation $EW

Robeco Institutional Asset Management B.V. trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 743,309 shares of the medical research company’s stock after selling 5,594 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.13% of Edwards Lifesciences worth $58,134,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $330,881,000. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Edwards Lifesciences by 7,805.0% during the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock worth $59,822,000 after purchasing an additional 814,917 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock worth $65,381,000 after purchasing an additional 709,648 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Edwards Lifesciences by 37.0% during the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company’s stock worth $141,105,000 after purchasing an additional 525,822 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Up 0.5%

Shares of EW opened at $76.66 on Friday. The company has a market capitalization of $45.01 billion, a P/E ratio of 11.03, a PEG ratio of 3.67 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The business’s 50 day simple moving average is $78.55 and its 200-day simple moving average is $75.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Argus raised Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Piper Sandler upped their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.